Livzon Research Institute

Livzon Research Institute was established in 1985 in the same year as Livzon Group. After more than 30 years of development, it has become a technology research and development center that meets international standards and undertakes a number of major new drugs in the 12th and 13th Five-Year Plan. Created a special project and has been successfully completed.

Significant achievements have been made in the fields of digestion, cardiovascular, anti-infection, and neuropsychiatry: Livzon Dele is a household name and is still the main force in eradicating Helicobacter pylori; Livzoni (Valacyclovir hydrochloride) is the first choice for the treatment of herpes zoster Medicine; Livzon Xinle (isosorbide mononitrate) is an essential medicine for coronary heart disease; Dantrolene sodium is a life-saving medicine and orphan medicine for the treatment of febrile hyperthermia. Ilaprazole is the first 1.1-type patented new drug in the digestive field in China. It took more than 10 years to develop successfully. It was the first to be marketed in the world in 2008 and filled the domestic gap. It is a milestone in China’s new drug R&D. It was selected as the “National Key New Drug” in 2014. Product", won the second prize of National Science and Technology Progress Award, National Patent Excellence Award, and Guangdong Patent Gold Award. In 2017, the 2.2-category new drug ilaprazole sodium for injection was approved for production, which is a major breakthrough in the development of Livzon Research Institute. The research institute is located in the scientific research building of Livzon Industrial Park, with a laboratory area of ​​more than 7,000 square meters, equipped with more than 400 sets of internationally advanced analytical testing instruments, formulation research and chemical synthesis equipment, with a total value of more than 40 million yuan.

There are nearly 140 employees, and it is a professional R&D team with overseas returnees as the academic leader, 91% of whom have a bachelor degree or above, a member of the National Pharmacopoeia Committee, and 1 National Talent Project. The research and development team of the institute has rich experience in industrial transformation, and the clinical research team has complete research and development experience of innovative drugs and has undergone the most stringent verification. In addition to ordinary oral solids and injections, new technologies such as slow and controlled release technology, nanotechnology, liposomes, and micelles have been fully deployed.

In the past five years, the institute has obtained 4 production approvals, 9 clinical approvals/acquisitions, and 2 production declarations. There are currently more than 20 research projects, including 5 clinical/BE research projects. A total of 95 invention patents were applied for and 72 were authorized, including 66 domestic authorizations and 6 foreign authorizations.

The Institute will continue to uphold the corporate culture value of "Patients' Quality of Life First", and be guided by human health, optimize the research and development model, and build a research and development testing center that combines innovation and high-end preparations, making the Institute the pride and support of Livzon Group Livzon Group has always maintained its leading position in the pharmaceutical industry.